RCS - Tissue Regenix Group - First EU shipment & new distributor agreements

Tissue RegenixAnnouncement

06/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240206:nRSF0928Ca&default-theme=true

RNS Number : 0928C  Tissue Regenix Group PLC  06 February 2024

Tissue Regenix Group plc

('Tissue Regenix', the 'Company', or the 'Group')

 

First shipment and sale of allograft products in the EU following HPRA
approval

&

New distributor agreements signed for Turkey and Ireland

 

Tissue Regenix (AIM: TRX), the regenerative medical device company, announces
that the first order of its allograft products has been shipped from its
third-party Irish logistics hub, Biostór Ireland Ltd, following approval from
the Irish Health Products Regulatory Authority ('HPRA') in October 2023
(https://www.londonstockexchange.com/news-article/TRX/hpra-approval-distribution-agreement-in-spain/16186366)
. The Irish logistics hub provides a central European location for the
distribution of Tissue Regenix's allograft products throughout the European
Union ('EU'), facilitating increased shipments across the EU and aiding the
potential for further partnerships and distributor contracts within these
countries.

 

Tissue Regenix also announces that it has signed two new distributor
agreements for its allograft products in Turkey and Ireland (including
Northern Ireland). These agreements cover the dental and orthopaedic markets
and continue the expansion of the Company's EU coverage, following the
recently announced exclusive distributor agreement in Spain
(https://www.londonstockexchange.com/news-article/TRX/hpra-approval-distribution-agreement-in-spain/16186366)
with Spineart España SLU.

 

These developments are in line with the Group's commercial strategy of
expanding its distribution network and growing market share in other
jurisdictions outside the US in H2 2023.

 

Daniel Lee, Chief Executive Officer of Tissue Regenix Group plc, commented:
"At our interims we outlined our intention to more broadly distribute
allograft tissue products, and I am pleased to report the positive progress we
are making against this growth pillar. These new distributor contracts,
alongside the first shipment of products from our Irish logistics hub, are a
great step forward in the Company's EU expansion plan into markets where we
gain approvals and demonstrate the effectiveness of our ongoing 4S strategy as
we scale the business outside of the US."

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                               via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Charlotte Edgar / Alice Woodings                                   TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADGGDDUGGDGSU